MARC details
| 000 -LEADER |
|---|
| fixed length control field |
03410cam a2200325 a 4500 |
| 003 - CONTROL NUMBER IDENTIFIER |
|---|
| control field |
EG-GiCUC |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
201206s2020 ua dh f m 000 0 eng d |
| 040 ## - CATALOGING SOURCE |
|---|
| Original cataloging agency |
EG-GiCUC |
| Language of cataloging |
eng |
| Transcribing agency |
EG-GiCUC |
| 041 0# - LANGUAGE CODE |
|---|
| Language code of text/sound track or separate title |
eng |
| 049 ## - LOCAL HOLDINGS (OCLC) |
|---|
| Holding library |
Deposite |
| 097 ## - Thesis Degree |
|---|
| Thesis Level |
M.Sc |
| 099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) |
|---|
| Classification number |
Cai01.08.08.M.Sc.2020.Ah.F |
| 100 0# - MAIN ENTRY--PERSONAL NAME |
|---|
| Personal name |
Ahmed Mostafa Elmohamady |
| 245 10 - TITLE STATEMENT |
|---|
| Title |
Formulationand evaluation of vesicular system contain anti-emetic drug for trans-mucosal nasal drug delivery / |
| Statement of responsibility, etc. |
Ahmed Mostafa Elmohamady ; Supervised Mohamed Ahmed Elnabarawi , Mahmoud Hassan Teaima , Amir Ibrahim Mohamed |
| 246 15 - VARYING FORM OF TITLE |
|---|
| Title proper/short title |
صياغة وتقييم نظام حويصلى يحتوى على مضاد للقىء للتوصيل الدوائى عبر الغشاء المخاطى الانفى |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. |
|---|
| Place of publication, distribution, etc. |
Cairo : |
| Name of publisher, distributor, etc. |
Ahmed Mostafa Elmohamady , |
| Date of publication, distribution, etc. |
2020 |
| 300 ## - PHYSICAL DESCRIPTION |
|---|
| Extent |
224 P. : |
| Other physical details |
charts , facimiles ; |
| Dimensions |
25cm |
| 502 ## - DISSERTATION NOTE |
|---|
| Dissertation note |
Thesis (M.Sc.) - Cairo University - Faculty of Pharmacy - Department of Pharmaceutics |
| 520 ## - SUMMARY, ETC. |
|---|
| Summary, etc. |
The supportive care of patients receiving antineoplastic treatment has dramatically improved over the past two decades. The development of effective means to prevent nausea and vomiting arising from chemotherapy serves as one of the most important examples of this progress. Patients beginning cancer treatment consistently list chemotherapy-induced nausea and vomiting as one of their greatest fears. Inadequately controlled emesis impairs functional activity and quality of life for patients, increases the use of health care resources, and may occasionally compromise adherence totreatment. Ondansetron Hcl represents the class of (5-HT3) serotonin receptor antagonist, which is commonly employed as anti-emetic in combination with antiulcer and anticancer agents. It is indicated for the preventing of nausea and vomiting associated with cancer chemotherapy, radiotherapy or anaesthesia andsurgery. Intranasal administration is an attractive option for local and systemic delivery of many therapeutic agents.The nasal mucosa compared to other mucosae is easily accessible. Intranasal drug administration is non- invasive, essentially painless and particularly suited for children. Application can be performed easily by patients or by physicians in emergency settings. Intranasal drug delivery offers a rapid onset of therapeutic effects (local or systemic). Vesicular systems are a novel means of drug delivery that can enhance bioavailability of encapsulated drug and provide therapeutic activity in a controlled manner for a prolonged period. Niosomes are non-ionic surfactant vesicles in aqueous media resulting in closed bilayer structures that can be used as carriers of amphiphillic and lipophilic drugs.To prevent rapid mucociliary clearance and improve the residence time Thermo reversible in-situ gelling system is utilized. These systems adhere onto the mucus membrane and increase the residence time.This intensifies the contact between nasal membrane and the drug and facilitates the drug absorption, which results in augmented bioavailability |
| 530 ## - ADDITIONAL PHYSICAL FORM AVAILABLE NOTE |
|---|
| Additional physical form available note |
Issued also as CD |
| 653 #4 - INDEX TERM--UNCONTROLLED |
|---|
| Uncontrolled term |
Niosomes |
| 653 #4 - INDEX TERM--UNCONTROLLED |
|---|
| Uncontrolled term |
Ondansetron HCl |
| 653 #4 - INDEX TERM--UNCONTROLLED |
|---|
| Uncontrolled term |
Poloxamer 407 |
| 700 0# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Amir Ibrahim Mohamed , |
| Relator term |
|
| 700 0# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Mahmoud Hassan Teaima , |
| Relator term |
|
| 700 0# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Mohamed Ahmed Elnabarawi , |
| Relator term |
|
| 905 ## - LOCAL DATA ELEMENT E, LDE (RLIN) |
|---|
| Cataloger |
Nazla |
| Reviser |
Revisor |
| 905 ## - LOCAL DATA ELEMENT E, LDE (RLIN) |
|---|
| Cataloger |
Shimaa |
| Reviser |
Cataloger |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Source of classification or shelving scheme |
Dewey Decimal Classification |
| Koha item type |
Thesis |
